{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:27Z","timestamp":1791518727582,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00415-018-8813-z","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T02:49:04Z","timestamp":1520822944000},"page":"1145-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration"],"prefix":"10.1007","volume":"265","author":[{"given":"Shinji","family":"Aoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"8813_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"8813_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"11","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 11:925\u2013933","journal-title":"Lancet Neurol"},{"key":"8813_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goeltz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"8813_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"8813_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742\u2013750","journal-title":"Ann Neurol"},{"key":"8813_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372:1476\u20131478","journal-title":"N Engl J Med"},{"key":"8813_CR7","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1212\/NXI.0000000000000274","volume":"3","author":"M Baharnoori","year":"2016","unstructured":"Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3:e274","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2011","key":"8813_CR8","first-page":"292","volume":"69","author":"CH Polman","year":"2010","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2010) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2011):292\u2013302","journal-title":"Ann Neurol"},{"key":"8813_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"8813_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"key":"8813_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/jmv.23841","volume":"86","author":"V Sroller","year":"2014","unstructured":"Sroller V, Ham\u0161\u00edkov\u00e1 E, Ludv\u00edkov\u00e1 V, Vochozkov\u00e1 P, Kojzarov\u00e1 M, Fraiberk M, Sal\u00e1kov\u00e1 M, Mor\u00e1vkov\u00e1 A, Forstov\u00e1 J, N\u011bme\u010dkov\u00e1 S (2014) Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population. J Med Virol 86:1560\u20131568","journal-title":"J Med Virol"},{"key":"8813_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","volume":"91","author":"A Antonsson","year":"2010","unstructured":"Antonsson A, Green AC, Mallitt KA, O\u2019Rourke PK, Pawlita M, Waterboer T, Neale RE (2010) Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 91:1849\u20131853","journal-title":"J Gen Virol"},{"key":"8813_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ane.12699","volume":"136","author":"M Cambron","year":"2017","unstructured":"Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P (2017) JCV serology in time: 3\u00a0years of follow-up. Acta Neurol Scand 136:54\u201358","journal-title":"Acta Neurol Scand"},{"key":"8813_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1348-0421.1982.tb00254.x","volume":"26","author":"F Taguchi","year":"1982","unstructured":"Taguchi F, Kajioka J, Miyamura T (1982) Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 26:1057\u20131064","journal-title":"Microbiol Immunol"},{"key":"8813_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/cen3.12191","volume":"6","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Kinoshita M, Tanaka K (2015) Anti-John Cunningham virus index in Japanese patients with multiple sclerosis and neuromyelitis optica-related disorder. Clin Exp Neuroimmunol 6:309\u2013311","journal-title":"Clin Exp Neuroimmunol"},{"key":"8813_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ene.12304","volume":"21","author":"C Bozic","year":"2014","unstructured":"Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 21:299\u2013304","journal-title":"Eur J Neurol"},{"key":"8813_CR17","doi-asserted-by":"crossref","unstructured":"Paz SC, Branco LP, Pereira MAC, Spessotto CV, Fragoso YD (2018) Systematic review of published data on the worldwide prevalence of John Cunningham virus (JCV) in patients with multiple sclerosis. Epidemiol Health (in press)","DOI":"10.4178\/epih.e2018001"},{"key":"8813_CR18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","volume":"86","author":"TV Gyang","year":"2016","unstructured":"Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L (2016) Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 86:1843\u20131845","journal-title":"Neurology"},{"key":"8813_CR19","first-page":"Article ID 3078","volume":"2014","author":"J Killestein","year":"2014","unstructured":"Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijilens ML, Wattjes MP (2014) PML-IRIS during fingolimod diagnosed after natalizumab discontinuation. Case Rep Neurol Med 2014:Article ID 307872","journal-title":"Case Rep Neurol Med"},{"key":"8813_CR20","first-page":"5876798","volume":"2016","author":"T Sinnecker","year":"2016","unstructured":"Sinnecker T, Othman J, K\u00fchl M, Metz I, Niendorf T, Kunkel A, Paul F, Wuerfel J, Faiss J (2016) Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. Case Rep Neurol Med 2016:5876798","journal-title":"Case Rep Neurol Med"},{"key":"8813_CR21","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/1352458515599681","volume":"21","author":"J Raffel","year":"2015","unstructured":"Raffel J, Gafson AR, Malik O, Nicholas R (2015) Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 21:1833\u20131838","journal-title":"Mult Scler"},{"key":"8813_CR22","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00415-017-8643-4","volume":"264","author":"J Peters","year":"2017","unstructured":"Peters J, Williamson E (2017) Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol 264:2409\u20132412","journal-title":"J Neurol"},{"key":"8813_CR23","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","volume":"3","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, G\u00f6bel K, Brassat D, Wiendl H (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3:e195","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8813_CR24","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1212\/NXI.0000000000000199","volume":"3","author":"A Javed","year":"2016","unstructured":"Javed A, Reder AT (2016) Rising JCV-Ab index during natalizumab therapy for MS: inauspicious for a highly efficacious drug. Neurol Neuroimmunol Neuroinflamm 3:e199","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8813_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","volume":"29","author":"AM Subei","year":"2015","unstructured":"Subei AM, Cohen JA (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29:565\u2013575","journal-title":"CNS Drugs"},{"key":"8813_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355\u2013360","journal-title":"Nature"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8813-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8813-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8813-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T20:30:53Z","timestamp":1552336253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8813-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["8813"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8813-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All patients provided informed consent prior to their inclusion to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of Chiba University School of Medicine (No.842) and all participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}